Biocon surges 4%, launches diabetic drug in Japan

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol BureauShare prices of Biocon advanced 4.4 percent intraday Friday as has launched Insulin Glargine in Japan.The company's partner FUJIFILM Pharma has launched Insulin Glargine in Japan, for which it had received Japanese regulator approval in last quarter.Insulin Glargine BS Injection Kit has been developed and manufactured by Biocon and is being commercialized by FUJIFILM Pharma in Japan, which will provide a high quality, affordable biosimilar basal Insulin Glargine for diabetes patients in Japan.Kiran Mazumdar-Shaw, Chairperson of Biocon said, "We believe with FUJIFILM Pharma's commercial network, we will enable access to this world-class, prefilled disposable pen for better diabetes management for patients in Japan."The company's board meeting will be held on July 21, 2016, to approve the un-audited financial results for the quarter ended on June 30, 2016 (Q1).Deven Choksey of KR Choksey Investment Managers told CNBC-TV18, "For the last few years, Biocon has not been performing as much as its potential is. Now that the company has started performing and the potential is being exercised, to my mind that would be the comfort factor for the investors to come into this particular stock.""I would be a buyer in this particular stock in every fall or a correction as I see it. In fact, many of the pharmaceutical companies I find are giving an opportunity to buy at a corrective level. So, certainly this could be one of them," he said.At 12:00 hrs Biocon was quoting at Rs 715, up Rs 2.30, or 0.32 percent on the BSE.Posted by Rakesh Patil